Entries by Thomas Gabrielczyk

Sino Biological, Inc. to be Featured on Worldwide Business with kathy ireland®

Sino Biological, a biotechnology company which provides biological research reagents and related technical contract research services, will be featured on Worldwide Business with kathy ireland, airing on FOX Business Network, Bloomberg International and other outlets as sponsored content. Hosted by business mogul Kathy Ireland, this award-winning television series takes an in-depth look at companies around the world currently impacting different sectors of business and society. Dr. Rob Burgess, Chief Business Officer for Sino Biological, will be interviewed.

Regulatory & methodological trends in the lab

What started in 2013 as an attempt – to offer experts in analytical and microbiological quality control, contract laboratories, representatives from authorities and service providers an
industry event and a platform for exchanging knowledge and  experience – has now become a firmly established date in the events calendar.

Automation is key to saving lives

Cell and Gene Therapy Processing?Personalised tumour treatments are expensive. This particularly applies to individual cancer therapies based on gene-modified T cells. Currently, they are produced manually or, at best, in a partially-automated process. In a collaboration project ProCell for Patient, two hospitals are currently working with Optima Pharma to develop an automated unit for the decentralised production of a CAR-T cell product in treatment centres.

Accelerate development of adoptive cell therapies

The success of any adoptive cell therapy lies in how effectively and selectively engineered immune cells interact and kill cancer cells. Functional phenomics enables insights that can dramatically accelerate the development of next-gen cell therapies. evorion biotechnologies brings functional phenomics to pharma and biotech partners via exclusive access to a unique, proprietary pipeline for in-depth multi-modal analysis of thousands of cell-cell interactions at single-cell resolution.

Aseptic Closed Small-Volume Processing: Today’s Option`s

Small-volume biopharmaceutical processes continue to grow as more biopharmaceutical, cell therapy and gene therapy companies develop products. A 2021 Association for Regenerative Medicine (ARM) report states that there are 1,085 cell, gene and tissue-based therapy developers worldwide. These companies are engaged in many small-volume (<10L) processes including early-stage drug development and autologous therapies.

Let Excelya recruit the right people for the early phase

Early phase clinical trials require expert support, often across many service areas and specialisms. Recruitment for trials can be complicated, with less flexibility and higher costs as you attempt to acquire top talent on a project-only basis. That’s why CROs are becoming increasingly indispensable. CROs offer fully formed, multi-skilled teams ready to go, who you can bring on board as and when needed.